New Jersey · 2026-2027 Regular Session · Bill

A 1636: Classifies 7 Hydroxymitragynine as Schedule I drug and bans sale of products containing substance.

In committee Last action January 13, 2026: Introduced, Referred to Assembly Consumer Affairs Committee

Plain-language summary

A 1636 is a bill introduced in the New Jersey House on January 13, 2026. According to its official title, it concerns: Classifies 7 Hydroxymitragynine as Schedule I drug and bans sale of products containing substance. Primary sponsor: Sean Kean (Republican). Most recent recorded action (January 13, 2026): Introduced, Referred to Assembly Consumer Affairs Committee.

Sponsors

Primary sponsor: Sean Kean (Republican).